| Date | Title | Description |
| 01.11.2024 | The Phase III clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved | SHENZHEN, China, Nov. 1, 2024 /PRNewswire/ -- On November 1, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Ltd., r... |
| 18.10.2024 | Chipscreen Biosciences: Pioneering New Frontiers in Liver and Cancer Treatments | In the realm of pharmaceuticals, innovation is the lifeblood. Chipscreen Biosciences, a trailblazer in drug development, is making waves with two promising candidates: Chiglitazar for metabolic associated steatohepatitis (MASH) and CS231295... |
| 17.10.2024 | Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets: Investigational New Drug (IND) Application Accepted | SHENZHEN, China, Oct. 17, 2024 /PRNewswire/ -- On October 17, 2024, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted the company's Investigational New Drug (IND) application for CS231295 ... |
| 15.10.2024 | Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting | SHENZHEN, China, Oct. 15, 2024 /PRNewswire/ -- On October 15, 2024, the list of selected candidates for the oral report of the American Association for the Study of the Liver (AASLD 2024) annual meeting was officially announced online. The ... |
| 19.07.2024 | Treatment of Type 2 diabetes with Chiglitazar combined with Metformin Approved for listing by the National Medical Products Administration | SHENZHEN, China, July 19, 2024 /PRNewswire/ -- On July 19, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") announced that it has received the Drug Registration Certificate approved a... |
| 30.04.2024 | National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma | SHENZHEN, China, April 30, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product Chidamide (Epidaza®) , an oral subtype-selectiv... |
| 19.10.2021 | Chipscreen Biosciences Announces NMPA New Drug Approval of Bilessglu® (Chiglitazar Sodium tablets) for ( Type 2 Diabetes) in China | SHENZHEN, China, Oct. 19, 2021 /PRNewswire/ -- SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (hereinafter referred to as: CHIPSCREEN), a China headquartered biopharmaceutical company developing and marketing novel drugs based on its unique tech... |
